Ascend Wellness Holdings (AAWH) Cost of Revenue (2020 - 2026)
Ascend Wellness Holdings (AAWH) posted quarterly Cost of Revenue of $72.1 million for Q1 2026, down 18.53% year-over-year from $88.4 million in Q1 2025, and down 4.47% quarter-over-quarter from $75.4 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Cost of Revenue (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Cost of Revenue history runs 7 years deep, the most recent figure standing at $72.1 million for Q1 2026.
- In Q1 2026, Cost of Revenue fell 18.53% year-over-year to $72.1 million; the TTM figure through Mar 2026 stood at $314.5 million (down 16.23% YoY), while the FY2025 annual figure was $330.9 million, down 12.32% from the prior year.
- Cost of Revenue for Q1 2026 stood at $72.1 million, down from $75.4 million in the prior quarter.
- The five-year high for Cost of Revenue was $100.0 million in Q2 2024, with the low at $61.6 million in Q1 2022.
- The 5-year median for Cost of Revenue is $85.9 million (2025), against an average of $83.2 million.
- The sharpest annual moves came in 2022 and 2026: Cost of Revenue soared 69.02% in 2022, then declined 18.53% in 2026.
- Ascend Wellness Holdings' Cost of Revenue stood at $70.6 million in 2022, then soared by 31.21% to $92.6 million in 2023, then retreated by 3.76% to $89.1 million in 2024, then declined by 15.39% to $75.4 million in 2025, then declined by 4.47% to $72.1 million in 2026.
- Business Quant data shows AAWH's Cost of Revenue at $72.1 million in Q1 2026, $75.4 million in Q4 2025, and $81.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Ascend Wellness Holdings | 85.26 Mn | 18.26 Mn | 45.49 Mn | 80.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.63 Mn |
| Jun 30, 2026 | 80.63 Mn |
| Mar 31, 2026 | 72.05 Mn |
| Mar 31, 2026 | 72.05 Mn |
| Dec 31, 2025 | 75.42 Mn |
| Dec 31, 2025 | 75.42 Mn |
| Sep 30, 2025 | 81.13 Mn |
| Sep 30, 2025 | 81.13 Mn |
| Jun 30, 2025 | 85.91 Mn |
| Jun 30, 2025 | 85.91 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Dec 31, 2024 | 89.14 Mn |
| Dec 31, 2024 | 89.14 Mn |
| Sep 30, 2024 | 97.92 Mn |
| Sep 30, 2024 | 97.92 Mn |
| Jun 30, 2024 | 99.96 Mn |
| Jun 30, 2024 | 99.96 Mn |
| Mar 31, 2024 | 90.37 Mn |
| Mar 31, 2024 | 90.37 Mn |